Prognostic significance of metastatic lymph node ratio in gastric cancer: a Western-center analysis.
Gastrectomy
Lymph node ratio
Metastatic lymph node ratio
Prognosis
Survival
Journal
BMC surgery
ISSN: 1471-2482
Titre abrégé: BMC Surg
Pays: England
ID NLM: 100968567
Informations de publication
Date de publication:
07 Aug 2023
07 Aug 2023
Historique:
received:
31
05
2023
accepted:
27
07
2023
medline:
9
8
2023
pubmed:
8
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Tumor-node-metastasis (TNM) staging is the central gastric cancer (GC) staging system, but it has some disadvantages. However, the lymph node ratio (LNR) can be used regardless of the type of lymphadenectomy and is considered an important prognostic factor. This study aimed to evaluate the relationship between LNR and survival in patients who underwent curative GC surgery. All patients who underwent radical gastric surgery between January 2014 and June 2022 were retrospectively evaluated. Clinicopathological features of tumors, TNM stage, and survival rates were analyzed. LNR was defined as the ratio between metastatic lymph nodes and total lymph nodes removed. The LNR groups were classified as follows: LNR0 = 0, 0.01 < LNR1 ≤ 0.1, 0.1 < LNR2 ≤ 0.25 and LNR3 > 0.25. Tumor characteristics and overall survival (OS) of the patients were compared between LNR groups. After exclusion, 333 patients were analyzed. The mean age was 62 ± 14 years. According to the LNR classification, no difference was found between groups regarding age and sex. However, TNM stage III disease was significantly more common in LNR3 patients. Most patients (43.2%, n = 144) were in the LNR3 group. In terms of tumor characteristics (lymphatic, vascular, and perineural invasion), the LNR3 group had significantly poorer prognostic factors. The Cox regression model defined LNR3, TNM stage II-III disease, and advanced age as independent risk factors for survival. Patients with LNR3 demonstrated the lowest 5-year OS rate (35.7%) (estimated mean survival was 30 ± 1.9 months) compared to LNR 0-1-2. Our study showed that a high LNR was significantly associated with poor OS in patients who underwent curative gastrectomy. LNR can be used as an independent prognostic predictor in GC patients.
Sections du résumé
BACKGROUND
BACKGROUND
Tumor-node-metastasis (TNM) staging is the central gastric cancer (GC) staging system, but it has some disadvantages. However, the lymph node ratio (LNR) can be used regardless of the type of lymphadenectomy and is considered an important prognostic factor. This study aimed to evaluate the relationship between LNR and survival in patients who underwent curative GC surgery.
METHODS
METHODS
All patients who underwent radical gastric surgery between January 2014 and June 2022 were retrospectively evaluated. Clinicopathological features of tumors, TNM stage, and survival rates were analyzed. LNR was defined as the ratio between metastatic lymph nodes and total lymph nodes removed. The LNR groups were classified as follows: LNR0 = 0, 0.01 < LNR1 ≤ 0.1, 0.1 < LNR2 ≤ 0.25 and LNR3 > 0.25. Tumor characteristics and overall survival (OS) of the patients were compared between LNR groups.
RESULTS
RESULTS
After exclusion, 333 patients were analyzed. The mean age was 62 ± 14 years. According to the LNR classification, no difference was found between groups regarding age and sex. However, TNM stage III disease was significantly more common in LNR3 patients. Most patients (43.2%, n = 144) were in the LNR3 group. In terms of tumor characteristics (lymphatic, vascular, and perineural invasion), the LNR3 group had significantly poorer prognostic factors. The Cox regression model defined LNR3, TNM stage II-III disease, and advanced age as independent risk factors for survival. Patients with LNR3 demonstrated the lowest 5-year OS rate (35.7%) (estimated mean survival was 30 ± 1.9 months) compared to LNR 0-1-2.
CONCLUSION
CONCLUSIONS
Our study showed that a high LNR was significantly associated with poor OS in patients who underwent curative gastrectomy. LNR can be used as an independent prognostic predictor in GC patients.
Identifiants
pubmed: 37550669
doi: 10.1186/s12893-023-02127-y
pii: 10.1186/s12893-023-02127-y
pmc: PMC10408136
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
220Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Surg Laparosc Endosc Percutan Tech. 2011 Dec;21(6):383-90
pubmed: 22146158
BMC Cancer. 2015 Oct 15;15:703
pubmed: 26471376
Ann Surg Oncol. 2023 Sep;30(9):5544-5557
pubmed: 37261563
Ann Surg. 2015 Dec;262(6):991-8
pubmed: 25563867
Eur J Surg Oncol. 2008 May;34(5):519-24
pubmed: 17624713
Indian J Surg Oncol. 2016 Mar;7(1):67-72
pubmed: 27065685
Ann Surg Oncol. 2015;22(6):1828-35
pubmed: 25388061
Gastric Cancer. 2012 Sep;15 Suppl 1:S70-88
pubmed: 22895615
Ann Surg. 2007 Apr;245(4):543-52
pubmed: 17414602
Ann Surg. 2012 Jan;255(1):50-8
pubmed: 21577089
CA Cancer J Clin. 2021 May;71(3):264-279
pubmed: 33592120
Int J Surg. 2013;11(5):419-24
pubmed: 23541652
Surg Oncol. 2015 Jun;24(2):84-8
pubmed: 25912951
World J Surg Oncol. 2018 Oct 4;16(1):198
pubmed: 30286762
World J Gastrointest Oncol. 2016 Jan 15;8(1):40-54
pubmed: 26798436
J Gastrointest Surg. 2023 Sep;27(9):1825-1836
pubmed: 37340110
Gastric Cancer. 2011 Jun;14(2):113-23
pubmed: 21573742
J Gastrointest Cancer. 2020 Sep;51(3):887-892
pubmed: 31691087
Am J Clin Oncol. 2013 Aug;36(4):325-30
pubmed: 22547011
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Med. 2023 May;12(9):10485-10498
pubmed: 36924361
BMC Surg. 2016 Sep 20;16(1):65
pubmed: 27646414
Transl Gastroenterol Hepatol. 2019 Apr 03;4:22
pubmed: 31143843
Int J Gen Med. 2022 Sep 12;15:7179-7187
pubmed: 36118182
Int J Surg. 2020 Oct;82:210-228
pubmed: 32800976
Ann Oncol. 2011 Sep;22(9):2049-2056
pubmed: 21310759
Updates Surg. 2021 Jun;73(3):865-872
pubmed: 33058054
Ann Surg Oncol. 2017 Nov;24(12):3683-3691
pubmed: 28895113
Scand J Gastroenterol. 2022 Jul;57(7):832-841
pubmed: 35293268
J Gastric Cancer. 2021 Mar;21(1):84-92
pubmed: 33854816
World J Surg Oncol. 2022 Dec 24;20(1):405
pubmed: 36566193
J Coll Physicians Surg Pak. 2021 Jul;30(7):805-810
pubmed: 34271780
J Visc Surg. 2022 Dec;159(6):471-479
pubmed: 34794901
World J Surg. 2020 Dec;44(12):4184-4192
pubmed: 32892273
J Clin Oncol. 2004 Jun 1;22(11):2069-77
pubmed: 15082726
Curr Oncol Rep. 2019 Jun 24;21(8):67
pubmed: 31236716
Int J Surg. 2018 Sep;57:76-83
pubmed: 30103072
Tumour Biol. 2016 Aug;37(8):11105-13
pubmed: 26912060
Eur J Surg Oncol. 2015 Jul;41(7):927-33
pubmed: 25913059
World J Gastroenterol. 2014 Oct 14;20(38):13791-803
pubmed: 25320517
Ann Surg Oncol. 2003 Nov;10(9):1077-85
pubmed: 14597447
J Gastrointest Oncol. 2021 Oct;12(5):2022-2034
pubmed: 34790370